Rheumatoid Arthritis Clinical Trials in San Antonio

Showing 861-880 of 2,360 trials

Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation

NCT00621894

The purpose of this study is to assess the ability of LGD-4665 given daily by mouth to increase platelet counts in the treatment of patients with ITP (immune thrombocytopenic purpura). LGD-4665 increased platelet counts safely and tolerably compared to placebo in healthy volunteers. This study will examine the safety, tolerability and efficacy of 7.5 mg capsules of LGD-4665 to increase platelets compared to placebo, randomized 2:1, during blinded treatment for 6 weeks. Evaluation of platelet counts, bleeding scores and safety parameters will be done weekly. All patients are eligible to continue on active, open LGD-4665 treatment for an additional 12 weeks with optimal adjustment of dose for each patient.

Immune Thrombocytopenic Purpura

GlaxoSmithKline23 participantsStarted Mar 2008

San Diego, California, United States • San Francisco, California, United States • Manchester, Connecticut, United States +12 more locations

TERMINATEDPhase 2< 1 mile

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

NCT03640481

This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of systemic therapy

Chronic Graft-versus-host-disease

Kadmon, a Sanofi Company159 participantsStarted Oct 2018

Phoenix, Arizona, United States • Tucson, Arizona, United States • Duarte, California, United States +32 more locations

Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Rheumatoid Arthritis Trials in Other Cities

Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery

Radiation Oncology Patient Medical Physics Intervention Study

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

The WEB-IT Clinical Study

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

MIRACLE of LIFE Study

Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

SpineJack System Postmarket Registry

NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

A Phase III Trial of e-TNS for the Acute Treatment of Migraine

Other Conditions in San Antonio